Publicación:
Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Bothrops atrox Snake Venom

dc.contributor.author Calderon, Henri Bailon es_PE
dc.contributor.author Coronel, Veronica Olga Yaniro es_PE
dc.contributor.author Rey, Omar Alberto Caceres es_PE
dc.contributor.author Alave, Elizabeth Gaby Colque es_PE
dc.contributor.author Duran, Walter Jhon Leiva es_PE
dc.contributor.author Rojas, Carlos Padilla es_PE
dc.contributor.author Arevalo, Harrison Montejo es_PE
dc.contributor.author Neyra, David Garcia es_PE
dc.contributor.author Perez, Marco Galarza es_PE
dc.contributor.author Bonilla, Cesar es_PE
dc.contributor.author Tintaya, Benigno es_PE
dc.contributor.author Ricciardi, Giulia es_PE
dc.contributor.author Smiejkowska, Natalia es_PE
dc.contributor.author Romao, Ema es_PE
dc.contributor.author Vincke, Cecile es_PE
dc.contributor.author Levano, Juan es_PE
dc.contributor.author Celys, Mary es_PE
dc.contributor.author Lomonte, Bruno es_PE
dc.contributor.author Muyldermans, Serge es_PE
dc.date.accessioned 2024-05-30T23:13:38Z
dc.date.available 2024-05-30T23:13:38Z
dc.date.issued 2020
dc.description.abstract Snake envenoming is a globally neglected public health problem. Antivenoms produced using animal hyperimmune plasma remain the standard therapy for snakebites. Although effective against systemic effects, conventional antivenoms have limited efficacy against local tissue damage. In addition, potential hypersensitivity reactions, high costs for animal maintenance, and difficulties in obtaining batch-to-batch homogeneity are some of the factors that have motivated the search for innovative and improved therapeutic products against such envenoming. In this study, we have developed a set of nanobodies (recombinant single-domain antigen-binding fragments from camelid heavy chain-only antibodies) against Bothrops atrox snake venom hemorrhagic and myotoxic components. An immune library was constructed after immunizing a Lama glama with whole venom of B. atrox, from which nanobodies were selected by phage display using partially purified hemorrhagic and myotoxic proteins. Biopanning selections retrieved 18 and eight different nanobodies against the hemorrhagic and the myotoxic proteins, respectively. In vivo assays in mice showed that five nanobodies inhibited the hemorrhagic activity of the proteins; three neutralized the hemorrhagic activity of whole B. atrox venom, while four nanobodies inhibited the myotoxic protein. A mixture of the anti-hemorrhagic and anti-myotoxic nanobodies neutralized the local tissue hemorrhage and myonecrosis induced by the whole venom, although the nanobody mixture failed to prevent the venom lethality. Nevertheless, our results demonstrate the efficacy and usefulness of these nanobodies to neutralize important pathologies of the venom, highlighting their potential as innovative therapeutic agents against envenoming by B. atrox, a viperid species causing many casualties in South America.
dc.description.sponsorship Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica - Concytec
dc.identifier.doi https://doi.org/10.3389/fimmu.2020.00655
dc.identifier.uri https://hdl.handle.net/20.500.12390/2874
dc.language.iso eng
dc.publisher Frontiers Media SA
dc.relation.ispartof FRONTIERS IN IMMUNOLOGY
dc.rights info:eu-repo/semantics/openAccess
dc.subject Immunology and Allergy
dc.subject Immunology es_PE
dc.subject.ocde http://purl.org/pe-repo/ocde/ford#3.01.03
dc.title Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Bothrops atrox Snake Venom
dc.type info:eu-repo/semantics/article
dspace.entity.type Publication
Archivos